# A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

> **NCT02198651** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 149 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Musculoskeletal and Connective Tissue Diseases

## Interventions

- **BIOLOGICAL:** Adalimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02198651
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-05
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-08-08
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198651, "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02198651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*